InvestWiser

Diamyd Medical AB (publ)

DMYD-BNasdaq StockholmHealthcareMarket value 142 m SEK
0.94SEK +1.6%
last day · Price as of 19 November 2026

The answer first

Does Diamyd Medical beat the market?

No, Diamyd Medical has not beaten the market over the last year.

Diamyd Medical−89.7%Stockholm (OMXSGI)+17.6%
  • The ranking · Quality, value and trend combined

    Better than 26% of Nordic stocks

    • Quality58
    • Value45
    • Trend15

    No. 114 of 195 in healthcare

Max for seven days

Follow Diamyd Medical with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 19 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Diamyd Medical

From today, at a price of 0.94 SEK. Write why you follow Diamyd Medical, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Diamyd Medical

Your first answer is free, no account needed.

Do you own Diamyd Medical, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Diamyd Medical and a few more. Free, no card.

Past year against the exchange and Super Stock
Diamyd Medical−89.7%Stockholm (OMXSGI)+17.6%Super Stock+46.4%
18 November 202519 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Diamyd Medical has fallen 89.7% over the past year, including dividends.
  • Overall, Diamyd Medical ranks better than 26% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 95.5%. The price is 98.6% below its peak now.

What do analysts think of Diamyd Medical?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

26

Quality, value and trend together. Better than 26% of Nordic stocks.

No. 114 of 195 in healthcare

Quality58
The company · Fundamentals: the accounts

Medium An average company: the accounts are neither especially strong nor weak.

No. 112 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.18
  • Asset turnoverSales divided by everything the company owns0.00
  • Return on equityProfit divided by equity−104.9%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value45
The price · Valuation: the multiples

Medium Fair price: about the same as a typical Nordic stock.

No. 55 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity0.6
  • P/SPrice divided by sales299.1
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend15
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 140 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−14.2%
  • 6 months−15.0%
  • 9 months−94.3%
  • 12 months−89.7%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−8.1%
3 years, per year
−48.6%
5 years, per year
−43.9%
10 years, per year
−16.4%
Largest fall, 3 years
−95.5%
From a peak to the bottom
From the peak now
−98.6%
How far the price is from the peak
Volatility, 1 year
108.8%
How much the price swings over a year
Beta, 1 year
0.27
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own Diamyd Medical

One fund we follow owns Diamyd Medical. The share is how much of the fund the stock makes up.

  • Sweden1

From the funds' latest known holdings.

About Diamyd Medical

Diamyd Medical AB (publ) is a company in healthcare, listed on Nasdaq Stockholm. By market value, Diamyd Medical is number 78 of 137 companies in healthcare on Nasdaq Stockholm. Diamyd Medical has not paid a dividend in the past twelve months. Of the three measures in the ranking, Diamyd Medical is strongest on quality, better than 58% of Nordic stocks. The share trades in SEK. It has around 39 employees.

Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. It develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. The company was incorporated in 1984 and is headquartered in Stockholm, Sweden.

See the full analysis of Diamyd Medical.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market